Taylor Szucs, PA
Physician Assistant · Shelby, NCNPI 1922698877
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 1,312 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,312 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$3K
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- plus $9K from 25 others
What the payments were for
- Food & beverage$21,24398%
- Education$4372%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 181 | $2,581 |
| AbbVie | 218 | $2,501 |
| Teva Pharmaceuticals USA, Inc. | 112 | $2,483 |
| Johnson & Johnson | 80 | $1,937 |
| Otsuka America Pharmaceutical, Inc. | 96 | $1,403 |
| Alkermes, Inc. | 57 | $1,283 |
| Supernus Pharmaceuticals, Inc. | 46 | $913 |
| Vanda Pharmaceuticals Inc. | 42 | $892 |
| Lundbeck LLC | 72 | $878 |
| Indivior Inc. | 43 | $850 |
| Almatica Pharma LLC | 79 | $822 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 42 | $822 |
| Axsome Therapeutics, Inc. | 31 | $587 |
| Corium, LLC | 45 | $526 |
| Bausch Health US, LLC | 26 | $485 |
| E.r. Squibb & Sons, L.L.C. | 20 | $434 |
| Merck | 21 | $381 |
| Braeburn Inc. | 17 | $370 |
| Tris Pharma Inc | 16 | $278 |
| Idorsia Pharmaceuticals US Inc | 15 | $246 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $245 |
| Ironshore Pharmaceuticals Inc. | 10 | $222 |
| Avanir Pharmaceuticals, Inc. | 6 | $113 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $107 |
| USWM, LLC | 6 | $106 |
| Collegium Pharmaceutical, Inc. | 4 | $76 |
| Noven Therapeutics, LLC | 3 | $45 |
| Noven Pharmaceuticals, Inc. | 1 | $33 |
| Bristol Myers Squibb | 1 | $32 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$207
- INVEGA TRINZA$207
- BRIXADI$109
- CAPLYTA$104
How this compares
$21,681 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 107 | $832,528 |
| IngrezzaValbenazine Tosylate | 53 | $455,939 |
| Invega TrinzaPaliperidone Palmitate | 35 | $328,877 |
| VraylarCariprazine Hcl | 160 | $237,714 |
| RexultiBrexpiprazole | 143 | $223,638 |
| Invega SustennaPaliperidone Palmitate | 36 | $132,051 |
| AustedoDeutetrabenazine | 13 | $127,213 |
| TrintellixVortioxetine Hydrobromide | 152 | $110,859 |
| FanaptIloperidone | 39 | $106,198 |
| UzedyRisperidone | 18 | $54,723 |
| BelsomraSuvorexant | 104 | $46,215 |
| QuviviqDaridorexant Hcl | 86 | $43,195 |
| LybalviOlanzapine/Samidorphan Malate | 25 | $42,951 |
| SpravatoEsketamine Hcl | 19 | $38,026 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $12,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy | $2,483 | $1,014,464138 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Spravato | $1,937 | $498,95490 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $2,581 | $455,93953 claims |
| AbbVieVraylar | $2,501 | $237,714160 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,403 | $223,638143 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $245 | $116,102166 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $892 | $106,19839 claims |
| MerckBelsomra | $381 | $46,215104 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $246 | $43,19586 claims |
| Alkermes, Inc.Lybalvi | $1,283 | $42,95125 claims |
| Axsome Therapeutics, Inc.Auvelity | $587 | $12,53412 claims |
| Almatica Pharma LLCLoreev Xr | $822 | $10,22724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Shelby
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
- Jay ClarkeArden$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.